Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 10:19:158.
doi: 10.1186/s12935-019-0865-3. eCollection 2019.

Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis

Bo Wang #  1 , Zijian Wang #  2 , Lizhi Han  3 , Song Gong  3 , Yanxue Wang  1 , Zhiwen He  1 , Yong Feng  3 , Zhaohui Yang  1
Affiliations
Review

Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis

Bo Wang et al. Cancer Cell Int. .

Abstract

Background: As a pivotal regulator, cyclin D3 gives play to a crucial value in conversion from the G1 stage to the S stage of cell cycle, which is implicated in tumor progression, especially proliferation and migration. Recent literatures have reported that cyclin D3 could predict survival time of malignancy patients. But, its prognostic role of cyclin D3 in neoplasms remains controversial.

Methods: Databases involving EMBASE, PubMed and Web of Science were carefully searched, and literatures investigating the prognostic effect of aberrantly expressing cyclin D3 among human cancers were collected for further analysis. We used both hazards ratios and its corresponding 95% confidence intervals to evaluate the connection among the survival rate of malignancy patients and the expression of cyclin D3.

Results: There were 13 eligible researches involving 16 cohorts and 2395 participants which were included in this study. The outcomes suggested that highly expressing cyclin D3 was significantly correlated with worse clinical prognosis of overall survival (HR 1.88; 95% CI 1.31-2.69) and disease specific survival (HR 2.68; 95% CI 1.35-5.31). But there existed no significant connection between the elevated expression of cyclin D3 with disease free survival (HR 2.65; 95% CI 0.83-8.46), recurrence-free survival (HR 2.86; 95% CI 0.82-9.96) and progression-free survival (HR 5.24; 95% CI 0.46-60.25) of diffident kinds of malignancy patients. Moreover, we discovered that elevated cyclin D3 expression was significantly connected with decreased overall survival in lymphoma (HR 3.72; 95% CI 2.18-6.36) while no significant relevance between highly expressing cyclin D3 and the overall survival in breast cancer was obtained (HR 2.12; 95% CI 0.76-5.91).

Conclusions: This meta-analysis demonstrated that highly expressing cyclin D3 might be an unfavorable prognostic biomarker for various malignancy patients, which can make great contributions to the clinical diagnosis and treatment.

Keywords: Cyclin D3; Malignancy; Meta-analysis; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The flow diagram indicated the process of study selection
Fig. 2
Fig. 2
Meta-analysis of the pooled HR of OS for malignancy patients
Fig. 3
Fig. 3
Results of subgroup analysis of pooled HR of OS for malignancy patients. a Subgroup analysis stratified by sample size. b Subgroup analysis stratified by type of cancer. c Subgroup analysis stratified by follow-up time. d Subgroup analysis stratified by NOS score. e Subgroup analysis stratified by source of HR
Fig. 4
Fig. 4
Meta-analysis of the pooled HR of OS for breast cancer (a) and lymphoma (b)
Fig. 5
Fig. 5
Meta-analysis of the pooled HR of DFS (a), RFS (b), PFS (c) and DSS (d)
Fig. 6
Fig. 6
Sensitivity analysis plot of pooled HR of OS (a), DFS (b), RFS (c), PFS (d) and DSS (e) for malignancy patients with abnormally expressed level of cyclin D3
Fig. 7
Fig. 7
Begg’s test (a) and Egger’s test (b) for publication bias
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013. - DOI - PubMed
    1. Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene. 1998;17(8):1027–1037. doi: 10.1038/sj.onc.1202016. - DOI - PubMed
    1. Gao CY, Zelenka PS. Cyclins, cyclin-dependent kinases and differentiation. Bioessays News Rev Mol Cell Dev Biol. 2010;19(4):307–315. doi: 10.1002/bies.950190408. - DOI - PubMed
    1. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol. 1996;8(6):805. doi: 10.1016/S0955-0674(96)80081-0. - DOI - PubMed